Genomic Interrogation of Secondary-Type Acute Myeloid Leukemia: Response and Outcomes to Contemporary Therapies,” published in the February 2025 issue of American Journal of Hematology by Senapati et ...
Moleculin Biotech (MBRX) has received FDA feedback and guidance on its IND amendment that has allowed a reduction in the size of its Phase 3 ...
Holdings provides an update from the Company’s ongoing Phase 1/1b clinical trial of BP1001-A in solid tumor patients and ...
The Damon Runyon Cancer Research Foundation and St. Jude Children’s Research Hospital have announced their newest class of ...
Researchers at the LKS Faculty of Medicine of the University of Hong Kong (HKUMed) have invented an oral formulation of ...
Compelling Patient Response Highlighted by Stable Disease and Significant Reduction in Blast Count After One Treatment Cycle HOUSTON, Feb. 12, 2025 (GLOBE NEWSWIRE) -- Bio-Path Holdings, Inc., (NASDAQ ...
Aptose Biosciences (NASDAQ:APTO;TSX:APS), a clinical-stage oncology stock, achieved positive safety and response results from ...
Acute Myeloid Leukemia (AML) is a hematological malignancy characterized by the rapid, uncontrolled growth of immature myeloid cells, leading to bone marrow ...
Cops for Kids with Cancer seeks to remove the financial burden for families impacted by a cancer diagnosis. This week they ...
NEW YORK - IN8bio, Inc. (NASDAQ:INAB), a biopharmaceutical company specializing in gamma-delta T cell therapies, reported ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback